|
Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape
Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now.
STATEMENT OF NEED
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Rana... |
|
|
Improving Outcomes in Hodgkin Lymphoma
This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now.
STATEMENT OF NEED
Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed ... |
|
|
Updates in Myelodysplastic Syndromes: Improving Patient Outcomes
This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now.
STATEMENT OF NEED
Myelodysplastic syndromes (MDS) comprise a heterogeneous group ofmyeloid malignanciesthat derive from abnormal multipot... |
|
Implementing the APA Guidelines for the Treatment of Schizophrenia: Caring for the Whole Person
In fall 2020, the American Psychiatric Association (APA) released new practice guidelines for the treatment of patients with schizophrenia. The new guidelines were eagerly awaited, because in the 16 years since the last update, many important discoveries about schizophrenia had been made. An overarching theme in the new APA guidelines is person-centered care. This approach is critical for improving outcomes; currently, as few as 14% to 50% of patients with schizophrenia achieve recovery. Howe... |
|
|
New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia
Gain expert insight on new treatment approaches to improve outcomes for patients with immune thrombocytopenia, including individualized treatment for patients who relapse and strategies to alleviate and improve supportive care. This discussion is led by Howard Liebman, MD, Professor of Medicine and Pathology at the University of Southern California Keck School of Medicine, and Allison Miller lmahiyerobo, MSN, APN, Advanced Practice Nurse at Hematology and Oncology Physicians of Englewood. Star... |
|
Newborn Screening: From RUSP to Reality
This is the first module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will provide clinicians with the fundamentals of newborn screening. |
|
|
Newborn Screening: Hemoglobinopathies and Newer Disorders on the RUSP
This is the fourth module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will focus on hemoglobinopathies and newer disorders which are part of the Recommended Uniform Screening Panel (RUSP) in order to better prepare clinicians to discuss positive results with new parents. |
|
|
Newborn Screening: Metabolic Conditions
This is the third module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will focus on metabolic diseases which are part of the Recommended Uniform Screening Panel (RUSP) in order to better prepare clinicians to discuss positive results with new parents. |
|
|
Newborn Screening: Talking to Parents
This is the second module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will focus on how to talk to parents about positive NBS results. |
|
|
Paroxysmal Nocturnal Hemoglobinuria (PNH) Highlights From ASH
At ASH, new information and data were presented on paroxysmal nocturnal hemoglobinuria (PNH)—a rare, acquired blood disease characterized by hemolytic anemia, bone marrow failure, thrombosis, and fatigue.
This accredited CME activity highlights the latest information about PNH from ASH and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients they may encounter with this rare condition. |
|
|
Research Highlights on Pyruvate Kinase (PK) Deficiency
This accredited CME activity provides a summary of the latest information about Pyruvate kinase (PK) deficiency that was presented at the 2021 American Society of Hematology Annual Meeting (ASH 2021). Since the Covid-19 pandemic limited the ability for specialists to attend ASH 2021 and discuss this latest research, this program provides a review by Rachael Grace, MD, of the most clinically-relevant information on PK deficiency presented during the meeting.
PK deficiency is a rare genetic b... |
|
|
Video Viewpoint Strategy Session: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer
This expert-led discussion, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. ... |
|
|
MPS II Research Highlights From the WORLDSymposium (Mucopolysaccharidosis type II; MPS II; Hunter syndrome)
This accredited CME activity, led by Barbara Burton, MD, Professor of Pediatrics at Northwestern University Feinberg School of Medicine, highlights the latest research about Mucopolysaccharidosis type II (MPS II; Hunter syndrome) presented at WORLDSymposium 2022 and provides expert analysis of its clinical relevance for busy members of the care team to help them care for patients they may encounter with this rare condition. MPS II, also known as Hunter syndrome, is a rare, progressive lysosoma... |
|
|
Video Viewpoint Strategy Session: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia
Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now.
STATEMENT OF NEED
Chemotherapy-induced neutropenia (CIN) is a potent... |
|
|
Podcast: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia
Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now.
STATEMENT OF NEED
Chemotherapy-induced neutropenia (CIN) is a potent... |
|
|
Video Viewpoint Strategy Session: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer
Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine. Start the activity now!
... |
|
|
Podcast: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer
This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of adv... |
|
|
Hereditary Angioedema (HAE) Research Highlights: 2022 AAAAI Annual Meeting
This accredited CME activity, led by Paula Busse, MD, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, provides a summary of the latest information about hereditary angioedema (HAE) that was presented at the American Academy of Allergy, Asthma, & Immunology 2022 (2022 AAAAI) Annual Meeting. This program was developed to provide a concise means to share the clinically relevant information presented at the meeting with health care professionals who my care for ... |
|
|
Diagnosis and Evidence-Based Management of T-Cell Lymphoma
STATEMENT OF NEED
T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this webinar, Aaron Goodman, MD, will update clinic... |
|
|
Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis
Learn more about myelofibrosis risk factors, novel therapies to slow disease progression and reduce symptoms, and strategies to maintain quality of life in this comprehensive activity presented by John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine. Start the activity now!
STATEMENT OF NEED
Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bon... |
|
|
Key Considerations in Managing Atopic Dermatitis in Black Patients
Statement of Need
Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong & Tay, 2017). Population studies within the United States have shown that AD disproportionately... |
|
|
Podcast: New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease
STATEMENT OF NEED
Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; howe... |
|
|
Diagnosis & Comorbidities in Cushing’s Disease: Incorporating the New Consensus Summary Into Your Practice
This 30 minute CME program highlights the latest expert consensus on best practices for diagnosing Cushing’s disease and managing the comorbidities commonly observed in persons with this rare disorder.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor. Optimal patient outcomes require an accurate diagnosis, proper selection of individualized treatment, and good management of the disease and its associated comorbidities.
The program feature... |
|
|
Updates in Medical Management of Cushing’s Syndrome: Incorporating the New Consensus Summary into Your Practice
This 30 minute CME program highlights the latest expert consensus on best practices for the treatment of persons with Cushing’s disease.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor. Optimal patient outcomes require an accurate diagnosis, proper selection of individualized treatment, and good management of the disease and its associated comorbidities.
The program features two experts, Maria Fleseriu, MD, Professor of Medicine and Neur... |
|
|
Advances in Gene Therapy for Lysosomal Diseases
This CME/CE activity highlights the current trends in gene therapy for lysosomal storage diseases as well as some of the safety concerns with such therapy.
This activity provides continuing education credit for Physicians, Physician Assistants, Nurse Practitioners, Nurses, Genetic Counselors as well as a statement of participation for other participants. |
|
|
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer
This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.
Statement of Need
An ... |
|
|
Updates in General Internal Medicine for Specialists 2023 - LIVE STREAMING or IN PERSON
Advances, Updates, Guidelines, and Best Practices in General Internal Medicine"Expressly for Specialists
Updates in General Internal Medicine for Specialists will be held online January 23-27, 2023. You have the option to attend either online as the course is live streamed or in person in Boston, MA. All sessions will be recorded and made available to all participants to view online, at your convenience, for 90 days following the conclusion of this program.
Overview
In this unique ... |
|
|
18th Annual Academic Surgical Congress
Eighteen years ago the first Academic Surgical Congress (ASC) was jointly held by the Association for Academic Surgery (AAS) and the Society of University Surgeons (SUS) to educate surgeons at every stage in their careers. The attendees are physicians, fellows and medical students who work in academic surgical facilities both national and internationally. |
|
|
Updates in Mantle Cell Lymphoma
Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin ly... |
|
|
Treatment Advances in Waldenstrom Macroglobulinemia
In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now.
STATEMENT OF NEED
Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphop... |
|
|
Expert Consult Series in Multiple Sclerosis"Updates, Clinical Scenarios, and Future Directions - Activity 3: Which S1P receptor modulator is right for your patient?
Multiple sclerosis (MS) is a chronic immune-modulated inflammatory and neurodegenerative disease of the central nervous system. Advances in understanding have led to the development and approval of multiple disease-modifying therapies (DMTs) that offer established safety and efficacy profiles, a variety of mechanisms of action, and different routes of administration to better match an individual patient’s clinical needs, preferences, and tolerance for risk. Issues that have come to the foref... |
|
|
Moving Forward in Alzheimer’s Disease: New Management Paradigms for Patients and Healthcare Systems
Target Audience
The educational design of this activity addresses the needs of neurology, psychiatry, and gerontology specialists involved in the treatment of patients with Alzheimer’s disease (AD).
Statement of Need/Program Overview
Alzheimer’s disease (AD) is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. The current understanding of the complex pathophysiology of AD has led to the development ... |
|
|
Ace the Case: Disease Progression in a 72-Year-Old Woman With Chronic Lymphocytic Leukemia Previously Treated With Venetoclax-Obinutuzumab
This activity utilizes a case study to discuss treatment options for an older patient with relapsed chronic lymphocytic leukemia (CLL). |
|
|
Ace the Case: 79-Year-Old Man With Lower Back Pain, Increasing Fatigue, and Right Rib Pain
This activity utilizes a case study to discuss treatment options for transplant-ineligible multiple myeloma (MM) patients. |
|
|
10-Night Great Barrier Reef CME AWAY® Cruise - Diabetes, Mood and Sleep Disorders, Osteoporosis, Thyroid Disease & Pain Management
Sydney, Australia • Eden, Australia • Airlie Beach, Qld, Australia • Cairns (Yorkey's Knob), Australia • Port Douglas, Australia • Willis Island (Cruising), Australia |
|
|
Multidisciplinary Viewpoints on NTM-LD Diagnosis and Management
In two virtual roundtables, a pulmonologist, infectious disease specialist, and clinical pharmacist share their experiences in addressing challenges in diagnosing and treating patients with NTM-LD. The expert panel discusses strategies for expediting diagnosis and improving patient care and outcomes within the context of a patient’s reflections on the path to diagnosis and their treatment experience. Through this approach, learners hear from a real-world patient as the multidisciplinary pane... |
|
|
Ace the Case: Disease Progression in a 65-Year-Old Man With Previously Treated Mantle Cell Lymphoma
This activity utilizes a case study to discuss treatment options for an older patient with relapsed mantle cell lymphoma (MCL). |
|
|
The ABC(DE) of ADTs in Advanced Prostate Cancer
Prostate cancer is the most common cancer in men in the U.S., responsible for an estimated 248,530 new cases and 34,130 deaths in 2021. For patients diagnosed with advanced prostate cancer, androgen deprivation therapy (ADT) plays a major role in treatment but may be associated with a broad range of adverse effects. Of these, increased risk of cardiovascular (CV) events is among the most serious, as cardiovascular disease (CVD) is the most common non-cancer cause of death in patients with pros... |
|
|
Shots in the Dark: How Can Clinicians Bridge the Immunization Gaps Widened by the COVID-19 Pandemic?
How can we bridge current immunization gaps further widened by the COVID-19 pandemic? Leading HPV and pneumococcal vaccine experts come together in this round-table discussion to share their experiences and strategies to increase vaccination rates. Additionally, faculty discuss the safety and efficacy data with the latest HPV and pneumococcal conjugate vaccine approvals. |
|
|
From Patients to People: Case Challenges in Individualizing Treatment for Adults with ADHD
In the United States, only 1 in 10 adults with ADHD receive appropriate therapy in any given year. This low number reflects the challenges that clinicians face when managing this disorder in adult patients. In particular, ADHD can manifest differently in adults than in children and teens, complicating diagnosis, especially if psychiatric comorbidities are present. Moreover, treatment strategies that worked well for patients in the past may no longer suffice, as they grow older and the demands ... |
|
|
Ace the Case: 71-Year-Old Woman With IgG Lambda Multiple Myeloma at Third Relapse
This activity utilizes a case study to discuss treatment options for multiple myeloma (MM) patients who have relapsed from previous therapies. |
|
|
Moving Forward With Movement Disorders
Moving Forward with Movement Disorders is a half-day course designed to inform and update primary care clinicians and general neurologists on the latest options and best practices for these challenging diseases, including evidence for improved outcomes when a movement disorder specialist is involved early on in treatment. With a focus on Parkinson’s Disease (PD), we will present an overview that will address gastrointestinal issues specific to these patients, contributors to fatigue, new med... |
|
|
Differentiating Early Signs of Alzheimer Disease From Normal Signs of Aging and Determining Best Next Steps.
Join us for this in-depth look at the early diagnosis of Alzheimer disease. Dr. James Galvin presents ways to differentiate Alzheimer disease from other neurodegenerative disorders, implement appropriate testing methods for earlier detection, and apply recent evidence to treatment selection to optimize patient outcomes. |
|
|
Cruising the Seychelles & Coastal Tanzania: Hot Topics in Medical, Dental & Public Health Issues
Luxury Expedition with Abercrombie & Kent on Le Jacques Cartier
March 11 – 24, 2023
Join PES on an unforgettable, luxury expedition cruise aboard the 148-guest Le Jacques Cartier with A&K’s renowned Expedition Team for 12 nights exploring coastal Tanzania and Seychelles, where idyllic beaches, lush emerald mountains, and UNESCO-protected wildlife reserves await!
CME/CE Lecture Seminars for Medical, Dental, Nursing and Allied Healthcare Professionals
This Seminar is planned for 14... |
|
|
Mitigating Disease Progression in Pompe Disease: Optimizing Early Diagnosis and Considering New Therapies to Improve Outcomes
Target Audience
The intended audience is inherited metabolic disease specialists, lysosomal storage disorder specialists, clinical geneticists, genetic counselors, cardiologists, hepatologists, neuromuscular specialists, neurologists, internal medicine, primary care providers, physician assistants and other HCPs involved in the diagnosis and management of Pompe disease
Program Overview
Pompe disease (PD) is a rare lysosomal storage disorder for which early diagnosis and treatment ... |
|
|
Clinical Cases in Pompe Disease: Optimizing Early Diagnosis and Considering New Therapies to Improve Outcomes
Program Overview
Pompe disease (PD) is a rare lysosomal storage disorder for which early diagnosis and treatment intervention with enzyme replacement therapy (ERT) are key to successful patient outcomes. This activity will discuss the keys to recognizing clinical presentations suggestive of PD, particularly in the absence of newborn screening, and the necessary steps for diagnosis. The clinical utility of ERT and the role of next-generation formulations will be examined alongside decision-m... |
|
|
T2D Management in Primary Care Practice: Addressing the Weight of it All
This expert-led activity offers a “how to” method for introducing strategies that support management of both dysglycemia and obesity. This activity highlights the ramifications of untreated obesity in patients with dysglycemia to underscore the importance of early obesity intervention. It also outlines ways to individualize obesity and dysglycemia management, recognize the benefits of earlier treatment intensification and weight loss, understand the latest data with incretin-based therapie... |
|
|
Pathways to Transfusion Independence & Reduced Health Complications: Advances for Lower-Risk MDS
In this dynamic case challenge format, expert faculty work through two patient cases and offer supporting data and practical experience to establish optimal recognition, diagnostic, and treatment practices, and discuss opportunities for shared decision making with patients. Learners are questioned about how they would proceed at different clinical decision points, and faculty commentaries offer recommendations and evidence for next steps. This activity outlines ways to identify and diagnose pa... |
|
|
Expert Consult Series in Multiple Sclerosis"Updates, Clinical Scenarios, and Future Directions - Activity 4: An emerging therapeutic class in MS
Multiple sclerosis (MS) is a chronic immune-modulated inflammatory and neurodegenerative disease of the central nervous system. Advances in understanding have led to the development and approval of multiple disease-modifying therapies (DMTs) that offer established safety and efficacy profiles, a variety of mechanisms of action, and different routes of administration to better match an individual patient’s clinical needs, preferences, and tolerance for risk. Issues that have come to the foref... |
|
|
19th Annual Mayo Clinic Women’s Health Update " Live/Livestream
This three-day conference (live and livestream) addresses a variety of women’s health issues that are commonly encountered in your practice, and impact women of all ages. The selected topics are clinically relevant and aimed at physicians and advanced practice providers. Conference sessions are led by subject matter experts from the Mayo faculty with case-based presentations, practice pearls, and interactive Q & A sessions. Optional small group discussions will address topics that are ch... |
|